Durata Therapeutics is a clinical development stage pharmaceutical venture that has a strong focus in finding treatment for infectious diseases. The company has developed dalbavancin for intravenous treatment of skin structure infections and acute bacterial skin diseases. As of, this novel therapeutics is on its phase III of clinical studies. They are also tapping the healing powers of this medicine to address other related infectious diseases. By advancing studies on this medical breakthrough, they are able to create solutions to highly unmet areas of medical needs and improving the quality of patient outcomes in hospitals and outpatient settings.
In November of 2014, it was announced that Durata Therapeutics was acquired by Actavis. Together with the portfolio of the latter, the two merged companies creates a formidable business that is fighting for the betterment of those afflicted with infectious diseases.